Analyst consensus rating
Entrada Therapeutics Analyst Rating: none
Direct answer
Entrada Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $19.00.
Forecast evidence checked October 1, 2026.
Get free Entrada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.35
- Average price target
- $19.00
- High price target
- $25.00
- Low price target
- $11.00
- Low target gap
- +73.2%
- Target upside
- +199.2%
- High target gap
- +293.7%
- Target range width
- 220.5%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 1, 2026
- Valid through
- October 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Entrada Therapeutics?
Entrada Therapeutics has a verified none consensus. The same dataset has an average price target of $19.00.
How far are Entrada Therapeutics's low and high targets from the recorded price?
The low target implies +73.2%, while the high target implies +293.7%.
How many analysts are included in Entrada Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Entrada Therapeutics's target upside or downside calculated?
The average target of $19.00 is divided by the recorded price of $6.35, then one is subtracted to produce +199.2%. This does not guarantee a future return.
When was Entrada Therapeutics's analyst forecast verified?
The data was verified on 2026-10-01. The dataset is valid through 2026-10-08.